Archive summary Clinical & research

StockWatch: Revolution’s Phase III Pancreatic Cancer Data Dazzles Investors, Analysts

In the trial’s overall (intent-to-treat) study population, daraxonrasib showed a median overall survival (OS) of 13.2 months, nearly double the 6.7 months demonstrated for standard-of-care chemotherapy, with a hazard ratio (HR) of 0.40 (p < 0.0001). Daraxonrasib also presented what Revolution called

Summary of reporting by genengnews April 20, 2026 1 min read Markdown